Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Note: Vaccine orders are only shipped out on Mon-Wed
Resmetirom (Rezdiffra TM ), a liver-directed thyroid hormone receptor- (THR-) agonist, received accelerated FDA approval in March 2024 as the first agent specifically indicated for non-cirrhotic MASH with moderate-to-advanced fibrosis (F2-F3), based on the MAESTRO-NASH trial demonstrating MASH resolution and fibrosis improvement
The larger needle makes it easy to pierce the tough rubber stoppers without coring them
more 3.7 | 147 61% 199 78 Buy at 28 Apply offers for maximum savings Apply offers for maximum savings
US$ 22.42
US$ 28.00
US$ 20.08
US$ 21.38
US$ 22.64
US$ 23.47
